Loading...
Pliant Therapeutics Q4 2024 Earnings Report
Pliant Therapeutics reported a net loss of $49.7 million for Q4 2024, with increased operating expenses primarily due to the BEACON-IPF Phase 2b/3 clinical trial.
Key Takeaways
Pliant Therapeutics experienced a net loss of $49.7 million in the fourth quarter of 2024, an increase from the prior-year quarter, mainly driven by higher research and development costs associated with the BEACON-IPF Phase 2b/3 clinical trial, which was discontinued following DSMB recommendation.
BEACON-IPF Phase 2b trial was discontinued due to an imbalance in unadjudicated IPF-related adverse events, despite early signs of efficacy on FVC.
Research and development expenses increased to $38.8 million, up from $33.2 million in the prior-year quarter, primarily due to the BEACON-IPF trial.
General and administrative expenses rose to $14.5 million, from $13.9 million, due to increased employee-related expenses.
The company reported a net loss of $49.7 million, compared to $41.1 million in the prior-year quarter.
Pliant Therapeutics
Pliant Therapeutics
Forward Guidance
Pliant Therapeutics expects its current cash, cash equivalents, restricted cash, and short-term investments to be sufficient to fund operations for the next 12 months and beyond.
Positive Outlook
- Phase 1 trial of PLN-101095 in solid tumors continues to enroll, with interim data expected in Q1 2025.
- PLN-101325 for muscular dystrophies is Phase 1 ready with CTA open in Australia.
- Company expects sufficient funds to cover operations for the next 12 months and beyond.
- Plans to analyze complete data from BEACON-IPF trial to evaluate next steps for bexotegrast's development.
- Appointment of Delphine Imbert as Chief Technical Officer brings extensive product development experience.
Challenges Ahead
- BEACON-IPF Phase 2b trial discontinued due to an imbalance in unadjudicated IPF-related adverse events.
- Discontinuation of BEACON-IPF trial may impact future development of bexotegrast.
- Increased net loss compared to prior year due to higher operating expenses.
- Reduced interest income on short-term investments contributed to higher net loss.
- The company acknowledges various risks and uncertainties related to product development and commercialization, including potential delays in clinical trials.